Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Kalaris Therapeutics, Inc.

CIK 1754068 KLRS·Biological Products · All EDGAR filings ↗

Progression

  1. Material weakness 10-K
  2. Finance chief departure 8-K +24d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Finance chief departure elevated Filing comparison

Kalaris Therapeutics, Inc.'s Chief Accounting Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Accounting Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Finance chief departure Filing comparison

Kalaris Therapeutics, Inc.'s Chief Financial Officer departed and a successor was named

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
normal
Source
SEC 8-K item code
Successor named
Yes
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Material weakness high Filing comparison

Kalaris Therapeutics, Inc. reported a material weakness in internal control

Internal control reported effective → Material weakness in internal control

If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. • We have identified material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future or fail to maintain an effective system of internal control over financial reporting, which may result in material misstatements of our financial statements. • We are early in our…
Evidence
Current state
material_weakness
Current state label
Material weakness in internal control
Direction
newly reported
Prior filed
2025-03-07
Prior form
10-K
Prior state
effective
Prior state label
Internal control reported effective
Remediation stated
No
Severity
high
Source
Item 9A internal control conclusion, compared with the prior filing
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗